Munetake Takada Selected Research

Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)

1/2024	EGFR-TKI rechallenge in patients with EGFR-mutated non-small-cell lung cancer who progressed after first-line osimertinib treatment: A multicenter retrospective observational study.
6/2023	Rechallenge of afatinib for EGFR-mutated non-small cell lung cancer previously treated with osimertinib: a multicenter phase II trial protocol (REAL study).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Munetake Takada Research Topics

Disease

2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2024 - 06/2023
1	Pneumonia (Pneumonitis) 01/2024
1	Disease Progression 01/2024

Drug/Important Bio-Agent (IBA)

2	osimertinibIBA 01/2024 - 06/2023
2	Tyrosine Kinase InhibitorsIBA 01/2024 - 06/2023
2	ErbB Receptors (EGF Receptor)IBA 01/2024 - 06/2023
1	AfatinibIBA 06/2023

Therapy/Procedure

1	Therapeutics 01/2024
1	Precision Medicine 06/2023